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Cardiovascular diseases arising from atherosclerosis are the 
leading causes of mortality and morbidity worldwide. 
Lipid-lowering agents have been developed in order to treat 
hypercholesterolemia, a major risk factor for atherosclerosis. 
However, the prevalence of cardiovascular diseases is 
increasing, indicating a need to identify novel therapeutic 
targets and develop new treatment agents. Adenosine 
receptors (ARs) are emerging as therapeutic targets in asthma, 
rheumatoid arthritis, cancer, ischemia, and inflammatory 
diseases. This study assessed whether LJ-1888, a selective 
antagonist for A3 AR, can inhibit the development of 
atherosclerosis in apolipoprotein E knock-out (ApoE−/−) mice 
who are fed a western diet. Plaque formation was significantly 
lower in ApoE−/− mice administered LJ-1888 than in mice not 
administered LJ-1888, without any associated liver damage. 
LJ-1888 treatment of ApoE−/− mice prevented western 
diet-induced hypercholesterolemia by markedly reducing 
low-density lipoprotein cholesterol levels and significantly 
increasing high-density lipoprotein cholesterol concentrations. 
Reduced hypercholesterolemia in ApoE−/− mice administered 
LJ-1888 was associated with the enhanced expression of genes 
involved in bile acid biosynthesis. These findings indicate that 
LJ-1888, a selective antagonist for A3 AR, may be a novel 
candidate for the treatment of atherosclerosis and hyper-
cholesterolemia. [BMB Reports 2018; 51(10): 520-525]
INTRODUCTION
Cardiovascular diseases including atherosclerosis are the 
leading causes of death worldwide (1-3). Hypercholesterolemia 
is considered a major risk factor for atherosclerosis, which has 
resulted in the development of medications aimed at lowering 
plasma cholesterol levels (4, 5). Because atherosclerosis is 
characterized by increased plasma levels of low-density 
lipoprotein cholesterol (LDL-chol) and reduced plasma 
concentrations of high-density lipoprotein cholesterol 
(HDL-chol) (6), agents that modify LDL-chol and HDL-chol 
levels are needed to prevent and improve the outcomes of 
atherosclerotic vascular diseases. Statins, which act as 
3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase 
inhibitors, are representative lipid-lowering medications that 
have shown protective effects in cardiovascular diseases by 
inhibiting cholesterol synthesis, enhancing the expression of 
LDL receptors on the surface of hepatocytes, and increasing 
anti-inflammatory responses (7). Other medications used to 
lower LDL-chol levels include cholesterol absorption inhibitors, 
bile acid sequestrants, and protein convertase subtilisin/kexin 
type-9 (PCSK-9) inhibitors (8, 9). Moreover, elevated plasma 
levels of HDL-chol have been closely associated with clinical 
benefits in patients with cardiovascular diseases (10). For 
example, cholesteryl ester transfer protein (CETP) inhibitors and 
HDL mimetics have been shown to regulate HDL-chol levels, 
suggesting that these agents may be therapeutically applicable 
in the prevention and/or treatment of cardiovascular diseases 
(10, 11). However, the worldwide morbidity and mortality rates 
of cardiovascular diseases remain high (12), indicating a need to 
identify new therapeutic targets and develop corresponding 
medications. 
Adenosine, an endogenous nucleoside, regulates various 
physiological processes, including neurotransmission, 
vasodilation, energy transfer, and signal transduction (13). 
Extracellular adenosine levels are low under normal 
physiological conditions, but increase in response to cellular 
damage resulting from inflammation, ischemia, hypoxia, and 
BMB Rep. 2018; 51(10): 520-525
www.bmbreports.org
LJ-1888 ameliorates atherosclerosis
Jong-Gil Park, et al.
521http://bmbreports.org BMB Reports
Fig. 1. LJ-1888 ameliorates the formation of atherosclerotic plaque 
in apolipoprotein E knock-out mice. (A) Quantification of Oil red 
O-stained areas on whole aortas from indicated groups (n = 
5-12). (B) Representative en face images of whole aortas from 
indicated groups. (C) Quantification of plaque areas on aortic 
sinuses of indicated groups (n = 5-12). (D) Representative images 
of Oil red O-stained areas of frozen sections of aortic sinuses 
from indicated groups. Data are shown as mean ± SEM. *P ＜
0.05, **P ＜ 0.01 versus ND group; #P ＜ 0.05, ##P ＜ 0.01 
versus WD group.
trauma (14). Four adenosine receptor (AR) subtypes, A1, A2A, 
A2B, and A3, mediate cellular signaling by adenosine and 
modulate the biological effects of adenosine in organs (15). 
Although the physiological roles of these four AR subtypes are 
partially redundant, they are encoded by separate genes and 
have unique functions (15). Therefore, selective agonists 
and/or antagonists have been developed for each AR subtype 
in order to treat various diseases (16). Investigations of A3 AR 
agonists and/or antagonists have provided the identification of 
pharmacological targets to treat myocardiac and cerebral 
ischemia, cancer, asthma, glaucoma, and renal fibrosis (17, 
18). LJ-1888 [(2R,3R,4S)-2-[2-chloro-6-(3-iodobenzylamino)-9H- 
purine-9-yl]-tetrahydrothiophene-3,4-diol] is a novel, selective, 
species-independent A3 AR antagonist (19) that has shown 
protective effects in renal fibrosis induced by unilateral 
ureteral obstruction (UUO) and transforming growth factor-1 
(TGF-1) (20). However, its ability to protect against the 
development of atherosclerosis has not yet been determined. 
This study therefore investigated the effects of LJ-1888 on the 
development of atherosclerosis in apolipoprotein E knock-out 
(ApoE−/−) mice who were fed a western diet (WD). 
Atherosclerotic plaque formation was significantly lower in 
LJ-1888-treated ApoE−/− mice than in untreated ApoE−/− 
mice. Moreover, LJ-1888 supplementation suppressed 
WD-induced hypercholesterolemia in ApoE−/− mice through 
lowering LDL-chol and raising HDL-chol levels. These effects 
of LJ-1888 were mechanistically associated with alterations in 
the expression of genes catalyzing bile acid biosynthesis. 
Taken together, these results suggest that LJ-1888 may be 
useful in the prevention and/or treatment of atherosclerosis 
and hypercholesterolemia.   
RESULTS
LJ-1888 ameliorates the formation of atherosclerotic plaques 
in apolipoprotein E knock-out mice
To explore the effects of the selective A3 AR antagonist LJ-1888 
on the development of atherosclerosis, six-week-old ApoE−/− 
mice were fed normal chow (ND) or a western diet (WD), with 
or without two dosages of LJ-1888 (0.025% and 0.05%), for 12 
weeks. Body weight (BW) gains were higher in WD fed than in 
ND fed ApoE−/− mice, but there were no differences among 
WD fed groups in BW gain (Supplementary Fig. 1A) or food 
intake (Supplementary Fig. 1B). After 12 weeks, the mice were 
sacrificed. The ratios of liver weight to BW were similar in all 
groups (Supplementary Fig. 1C), but the ratios of epididymal 
fat to BW were significantly higher in WD-fed than in ND-fed 
mice, with LJ-1888 supplementation having no effect on the 
ratio of epididymal fat to BW (Supplementary Fig. 1D). 
Isolated whole aortas of these mice, from the ascending to 
the femoral region, were dissected longitudinally and stained 
with Oil red O to analyze atherosclerotic plaque formation. 
Plaque formation was significantly greater in WD fed (3.79%) 
than in ND fed (1.58%) ApoE−/− mice. However, supplemen-
tation with 0.025% (2.02%) and 0.05% (2.30%) LJ-1888 
significantly inhibited WD-induced atherosclerotic plaque 
formation on the aortas of WD fed mice (Fig. 1A and B). To 
further validate the effects of LJ-1888 on atherosclerotic plaque 
formation, the aortic sinuses of hearts from the four groups of 
mice were dissected. As expected, atherosclerotic plaque 
formation on aortic sinuses was lowest in the ND fed group 
and highest in the WD fed group. Consistent with the plaque 
formation on the aortas, the plaque formation on the aortic 
sinuses was markedly lower in WD fed mice receiving 
0.025% and 0.05% LJ-1888 than in mice fed WD alone (Fig. 
1C and D). These results suggested that the selective A3 AR 
antagonist LJ-1888 has anti-atherosclerotic effects in ApoE−/− 
mice fed WD.  
LJ-1888 ameliorates hypercholesterolemia in western diet fed 
apolipoprotein E knock-out mice
Hypercholesterolemia is a major risk factor for the development 
of cardiovascular diseases including atherosclerosis (1). Elevated 
levels of LDL-chol in the circulation increase endothelial 
permeability, leading to the accumulation of lipids in the arterial 
walls and subsequently triggering atherosclerosis (3). In contrast 
to LDL-chol, HDL-chol contributes to the prevention of 
atherosclerosis development by enhancing reverse cholesterol 
transport (21). Therefore, we tested whether LJ-1888-mediated 
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Fig. 2. LJ-1888 ameliorates hypercholesterolemia in western diet 
fed apolipoprotein E knock-out mice. Plasma concentrations of (A) 
total cholesterol (T-chol), (B) low density lipoprotein cholesterol 
(LDL-chol), (C) high density lipoprotein cholesterol (HDL-chol), (D) 
triglycerides (TG), (E) glucose, (F) ALT, (G) AST, and (H) ALB of 
indicated groups (n = 5-12). Data are shown as mean ± SEM. 
*P ＜ 0.05, **P ＜ 0.01 versus ND group; #P ＜ 0.05, ##P ＜
0.01 versus WD group.
Fig. 3. LJ-1888 enhances the expression of bile acid synthesis 
related genes in the liver. Levels of expression of (A) cholesterol 
transport related genes and (B) bile acid biosynthesis genes in the 
livers of indicated groups (n = 4). Data are shown as mean ±
SEM. *P ＜ 0.05, **P ＜ 0.01 versus ND group; #P ＜ 0.05, ##P ＜
0.01 versus WD group.
anti-atherogenic effects are associated with reduced hyper-
cholesterolemia in ApoE−/− mice. Total cholesterol levels were 
found to be about two-fold higher in WD fed (1218 ± 40 mg/dl) 
than in ND fed (679 ± 41 mg/dl) ApoE−/− mice. Supplemen-
tation with 0.025% (719 ± 53 mg/dl) and 0.05% (964 ± 74 
mg/dl) LJ-1888 significantly reduced WD-mediated hypercholes-
terolemia compared to the WD group (Fig. 2A). Plasma 
LDL-chol levels showed a similar trend as total cholesterol, with 
WD fed mice having the highest level (279 ± 13 mg/dl), ND 
fed mice having the lowest level (97 ± 6 mg/dl), and mice fed 
WD plus 0.025% (151 ± 14 mg/dl) and 0.05% (216 ± 20 
mg/dl) LJ-1888 having significantly lower plasma LDL-chol 
concentrations than ApoE−/− mice fed WD alone (Fig. 2B). 
Supplementation with LJ-1888 also prevented the WD-mediated 
reduction in HDL-chol levels in ApoE−/− mice. HDL-chol levels 
were lower in WD fed (18 ± 1.2 mg/dl) than in ND fed (23 ± 
3.5 mg/dl) mice, whereas mice fed WD plus 0.025% (30 ± 1.9 
mg/dl) and 0.05% (30 ± 3.2 mg/dl) LJ-1888 had significantly 
higher HDL-chol concentrations than mice fed WD alone (Fig. 
2C). In contrast, although plasma triglyceride (TG) levels were 
lower in WD fed than in ND fed ApoE−/− mice, LJ-1888 
supplementation had no effect on plasma TG levels (Fig. 2D), 
and glucose levels were slightly, but not significantly, higher in 
WD fed than in ND fed mice (Fig. 2E). 
To test the liver toxicity of LJ-1888, we measured the serum 
concentrations of alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and albumin (ALB) in ApoE−/− mice. 
We found that ALT and AST levels, but not ALB levels, were 
higher in WD fed than in ND fed ApoE−/− mice (Fig. 2F-G), 
with LJ-1888 supplementation slightly ameliorating WD-induced 
liver damage. 
LJ-1888 enhances the expression of bile acid biosynthesis 
genes in the livers of apolipoprotein E knock-out mice 
Controlling lipoprotein and cholesterol levels is important for 
reducing the risk of atherosclerosis (1, 21, 22). Hypercholes-
terolemia may be ameliorated by lowering LDL-chol and TG 
concentrations and by increasing HDL-chol concentrations, 
using agents such as HMG-CoA reductase inhibitors, 
cholesterol absorption inhibitors, bile acid sequestrants, and 
proprotein convertase subtilisin/kexin type-9 (PCSK-9) 
inhibitors (7-9, 23, 24). We therefore assessed the mechanism 
by which LJ-1888 improves hypercholesterolemia in WD fed 
ApoE−/− mice. First, we measured the expression levels of 
cholesterol transport genes, including LDL receptor (Ldlr) and 
the ATP-binding cassette sub-family G member 5/8 (Abcg5/8), 
in the livers of the four groups of mice. Ldlr gene expression 
was significantly lower in the WD and WD+LJ0.025 groups 
than in the ND group, but this was not the case in the 
WD+LJ0.05 group, suggesting that Ldlr gene expression was 
not associated with the anti-atherogenic effects of LJ-1888 (Fig. 
3A). In addition, Abcg5/8 mRNA levels did not differ among 
the four groups (Fig. 3A), indicating that LJ-1888 does not 
ameliorate hypercholesterolemia in ApoE−/− mice by altering 
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Fig. 4. Effects of LJ-1888 on the expression of transcription factors 
for bile acid synthesis. Levels of expression of mRNAs encoding 
transcription factors regulating the synthesis of (A) bile acids and 
(B) lipids in the livers of indicated groups (n = 4). Data are 
shown as mean ± SEM. *P ＜ 0.05, **P ＜ 0.01 versus ND 
group; #P ＜ 0.05, ##P ＜ 0.01 versus WD group.
the expression of cholesterol transport genes. 
Next, we tested the effects of LJ-1888 on the expression of 
genes involved in bile acid biosynthesis (25). The classical 
pathway of bile acid synthesis is initiated by cholesterol 
7-hydroxylase (Cyp7a1), with bile acid intermediates further 
hydroxylated by sterol 12-hydroxylase (Cyp8b1). In contrast, 
the major enzymes in the alternative pathway of bile acid 
synthesis include sterol 27-hydroxylase (Cyp27a1) and 
25-hydroxycholesterol 7-hydroxylase (Cyp7b1) (26). LJ-1888 
supplementation induced the expression of bile acid 
biosynthetic genes. Cyp7al mRNA levels were significantly 
higher in both the WD+LJ0.025 and WD+LJ0.05 groups than 
in the ND group, but this was not the case in the WD group. 
Moreover, Cyp7a1 mRNA levels were markedly higher in the 
WD+LJ0.05 group than in the WD group. Cyp8b1, Cyp27a1, 
and Cyp7b1 mRNA levels were lower in the WD group than 
in the ND group, but were similar in the ND, WD+LJ0.025, 
and WD+LJ0.05 groups (Fig. 3B). 
To analyze the mechanism by which LJ-1888 induces the 
expression of these genes, including those encoding bile acid 
biosynthesis proteins, we analyzed the mRNA levels of the 
transcription factors involved in regulating enzymes for bile 
acid biosynthesis. Liver X receptors (LXRs) are a family of 
pivotal transcription factors involved in regulating lipid and 
cholesterol metabolism. LXR and LXR form heterodimers 
with the retinoic acid receptor (RXR), leading to transcription 
of various genes such as Cyp7a1 and sterol regulatory element 
binding factor 1c (Srebf1c) (26). We found that LXR (Nr1h3) 
mRNA levels were significantly higher in the WD+LJ0.025 
group than in the WD group (Fig. 4A) and tended to be higher 
in the WD+LJ0.05 group than in the WD group. In contrast, 
the levels of LXR (Nr1h2) and Rxra mRNAs did not differ 
among the four groups. 
Farnesoid X receptor (Fxr) suppresses Cyp7a1 transcription 
by controlling the expression of small heterodimer partner 
(Shp) (27). Paradoxically, Fxr mRNA levels were higher in the 
WD+LJ0.025 and WD+LJ0.05 groups than in the WD group. 
In addition, LJ-1888 supplementation altered the expression of 
genes encoding peroxisome proliferator-activated receptors 
(Ppars) and Srebf1c (Fig. 4B). These findings indicate that 
LJ-1888 may inhibit hypercholesterolemia in ApoE−/− mice by 
altering the expression of genes involved in bile acid 
biosynthesis.
DISCUSSION
Hypercholesterolemia, or high levels of cholesterol in the 
blood, enhances the risks of cardiovascular diseases, such as 
heart attack and stroke, induced by atherosclerosis (5, 6). High 
levels of circulating cholesterol generate sticky deposits on the 
walls of arteries, narrowing or blocking blood flow to organs 
and resulting in heart attack or stroke (22). Lifestyle 
modifications and various medications can lower blood 
cholesterol (6, 28). Statins are a class of HMG-CoA reductase 
inhibitors commonly used to reduce high cholesterol level that 
are effective in most individuals, reducing total cholesterol 
concentrations by about 50% on average (29). However, 
statins cannot be used in certain people, including pregnant 
women and patients with liver disease, and they also have side 
effects such as myositis, joint pain, stomach upset, and liver 
damage (30). Other drugs used to treat high LDL-chol, low 
HDL-chol, and high TG, alone or in combination with statins, 
include niacin, bile acid sequestrants, cholesterol absorption 
inhibitors, and fibric acid derivatives, but these agents also 
have side effects as well as low efficacy (31, 32). Therefore, it 
is necessary to identify novel targets and develop drugs in 
order to treat hypercholesterolemia and atherosclerosis.
Previous studies have shown that adenosine/AR signaling 
participates in the modulation of lipid availability, including 
lipolysis and cholesterol efflux (33, 34). Adenosine/A1 AR 
signaling has been shown to suppress lipolysis on adipocytes 
through the cyclic adenosine monophosphate (cAMP)-mediated 
inhibition of lipase activity (35, 36). Activation of A2A AR has 
also been shown to augment ATP-binding cassette transporter 
ABCA1 and sterol 27-hydroxylase (CYP27A1) expression, 
leading to enhancing cholesterol efflux from macrophages 
(37). However, the role of adenosine/A3 AR signaling in 
hyperlipidemia and atherosclerosis is unclear. Jones et al. has 
shown that A3 AR deficiency does not affect the formation of 
atherosclerotic plaque in ApoE−/− mice fed high-fat diet (30% 
fat) for five months, however, the levels of plasma cholesterol 
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and lipids were not determined in these mice (38). The 
differences in experimental design would affect any 
comparison of the results between the findings of Jones et al. 
and the present findings. In addition, LJ-1888 may have 
poly-pharmacological effects, even though LJ-1888 was 
developed as a selective A3 AR antagonist. Recently, Yu et al. 
presented the poly-pharmacological effects of A3 AR agonist 
(IB-MECA), which have shown the agonistic role of PPAR and 
antagonistic role of PPAR (39). Therefore, further study is 
needed to examine whether the role of LJ-1888 as a selective 
antagonist for A3 AR is responsible for its anti-atherogenic 
effects or not.  
Atherosclerosis is a chronic inflammatory disease induced by 
high levels of lipids and reactive oxygen species (3). This 
condition may be inhibited by targeting molecules involved in 
inflammatory responses and hypercholesterolemia (40, 41). 
LJ-1888 treatment was shown to block UUO- and 
TGF-1-induced activation of c-Jun N-terminal kinase and 
extracellular signal- regulated kinase involved in inflammatory 
responses (20). While we have not explored the role of LJ-1888 
in inflammation, the possibility that LJ-1888 shows 
anti-inflammatory properties in atherosclerosis remains. This 
study showed that LJ-1888 protected WD-fed ApoE−/− mice 
against the development of atherosclerosis by ameliorating 
hypercholesterolemia. Administration of LJ-1888 induced the 
expression of genes involved in bile acid biosynthesis, which 
may be related to the amelioration of hypercholesterolemia. 
Taken together, these findings show that LJ-1888, a selective 
antagonist for A3 AR, might be a novel candidate for preventing 
and/or treating atherosclerosis and hypercholesterolemia.
MATERIALS AND METHODS
Animal experiments
All animal studies were approved by the Institutional Animal 
Care and Usage Committee of Ewha Womans University 
(IACUC 2001-01-008). ApoE−/− (B6.KOR/Stm-Apoe) mice 
were purchased from Central Laboratory Animal Inc and 
housed under a 12-hour day-night cycle with free access to 
water and food in a specific pathogen-free system. 
Six-week-old ApoE−/− mice were randomly divided into four 
groups. The ND group consisted of five mice fed a normal 
chow diet supplemented with vehicle; the WD group 
consisted of 12 mice fed a western diet, consisting of 20% fat 
and 0.15% cholesterol (D09072603) and purchased from 
Research Diets Inc (USA), supplemented with vehicle; and the 
WD+LJ0.025 and WD+LJ0.05 groups consisted of 12 mice 
each fed a western diet supplemented with 0.025% and 
0.05% LJ-1888, respectively. 
Statistical analysis
All data shown in figures are presented as mean ± SEM. 
Statistical significance was determined by Student’s t-tests (for 
in vitro experiments) and Mann-Whitney U tests (for in vivo 
experiments).
Detailed materials and methods are available in the 
supplementary file.
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